“Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis”, J of Skin, vol. 4, no. 6, p. s98, Oct. 2020, doi: 10.25251/skin.4.supp.98.